Literature DB >> 26996116

Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?

Ragıp Ertaş1, Kemal Özyurt1, Sinem Yıldız1, Yılmaz Ulaş1, Abdullah Turasan1, Atıl Avcı1.   

Abstract

Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.

Entities:  

Keywords:  Chronic urticaria, Omalizumab, Adverse reaction

Mesh：

Substances：

Year:  2016        PMID： 26996116

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN： 1735-1502            Impact factor:   1.464


  6 in total

Review 1.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Efficacy and safety of Xiaofeng powder (xiao feng san) in treating urticaria: A protocol for a systematic review and meta-analysis of randomized controlled trials.

Authors:  Guoming Chen; Jinlong Zhao; Tengyu Chen; Zhaoping Zhang; Chuyao Huang; Zhirui Xu; Hua Xu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

3.  Does omalizumab treatment affect serum dehydroepiandrosterone sulphate levels in chronic idiopathic urticaria?

Authors:  Atıl Avcı; Deniz Avcı; Ragip Ertas; Mustafa Atasoy; Cigdem Karakukcu; Efşan Yontar; Yilmaz Ulas; Kemal Ozyurt
Journal:  Postepy Dermatol Alergol       Date:  2019-02-22       Impact factor: 1.837

4.  Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey.

Authors:  Hülya Nazik; Mehmet Kamil Mülayim; Perihan Öztürk
Journal:  Postepy Dermatol Alergol       Date:  2019-12-30       Impact factor: 1.837

5.  Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.

Authors:  Yudi Chen; Miao Yu; Xiaojie Huang; Ping Tu; Peikun Shi; Marcus Maurer; Zuotao Zhao
Journal:  World Allergy Organ J       Date:  2021-01-05       Impact factor: 4.084

6.  Urticaria and angioedema as possible reactions of omalizumab.

Authors:  Ozlem Ozbagcivan; Sevgi Akarsu; Turna Ilknur; Emel Fetil
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.